Peer-reviewed veterinary case report
Selegiline does not control pituitary-dependent Cushing's in dogs
By Braddock, J A et al.·Published in Australian veterinary journal·2004·Faculty of Veterinary Science, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Inefficacy of selegiline in treatment of canine pituitary-dependent hyperadrenocorticism.
- Species:
- dog
Plain-English summary
A group of dogs with pituitary-dependent hyperadrenocorticism (a condition causing excessive cortisol production) was treated with selegiline, a medication typically used for other conditions. Despite being safe and free of side effects, none of the dogs showed satisfactory improvement in their symptoms after treatment. The study monitored the dogs over several months but found that selegiline did not effectively control the disease. Pet owners should discuss alternative treatment options with their veterinarian if their dog has this condition.
People also search for: dog Cushing's disease treatment · selegiline for dogs · pituitary-dependent hyperadrenocorticism symptoms
Abstract
OBJECTIVE: To evaluate selegiline, a monoamine oxidase-B inhibitor, for treating dogs with pituitary-dependent hyperadrenocorticism. DESIGN: Prospective clinical trial using client-owned dogs with pituitary-dependent hyperadrenocorticism treated at The University Veterinary Centre, Sydney, from September 1999 to July 2001. PROCEDURE: Eleven dogs with pituitary-dependent hyperadrenocorticism treated with selegiline were monitored at days 10, 30 and 90 by clinical examination, tetracosactrin stimulation testing, urinary corticoid:creatinine ratio measurement and client questionnaire. Endogenous adrenocorticotropic hormone measurements were also performed on most dogs on days 0 and 90. No dog treated with selegiline had satisfactory control of disease. CONCLUSION: Selegiline administration was safe and free of side-effects at the doses used, but did not satisfactorily control disease in pituitary-dependent hyperadrenocorticism affected dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/15181926/